Stereotactic Body Radiotherapy: A Viable Option for Localized Prostate Cancer
Thursday, 17 October 2024, 09:37
Overview of Stereotactic Body Radiotherapy (SBRT)
Stereotactic body radiotherapy (SBRT) is gaining recognition as a viable alternative for localized prostate cancer (PC). A study published in the New England Journal of Medicine indicates that SBRT is noninferior to traditional radiotherapy methods, which is significant for men's health.
Study Design
- Participants: Patients with localized PC
- Intervention: SBRT (36.25 Gy in five fractions) vs. control radiotherapy (78 Gy in 39 fractions)
- Follow-Up Duration: Median of 74 months
Key Findings
- Five-year biochemical failure-free survival was 95.8% in SBRT vs. 94.6% in control.
- RTOG grade ≥2 genitourinary toxic effects were higher in the SBRT group (26.9% vs. 18.3%).
- Gastrointestinal toxic effects were similar across both treatments (10.7% vs. 10.2%).
Conclusion: The findings underscore that SBRT offers comparable outcomes to conventional approaches, promoting patient convenience in localized PC treatment.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.